---
schema_version: "secwatch.filing_event.v1"
accession: "0001140361-26-000971"
form_type: "8-K"
ticker: "BBIO"
cik: "0001743881"
company_name: "BridgeBio Pharma, Inc."
filed_at: "2026-01-12T23:59:59+00:00"
generated_at: "2026-05-16T10:54:32.295538+00:00"
event_type: "other_material"
sentiment: "positive"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# BridgeBio reports Q4 Attruby revenue $146M, cash $587.5M; plans two NDAs in H1 2026

## Summary
- Preliminary unaudited Q4 2025 Attruby net revenue $146M; full year $362.4M; cash, equivalents and securities $587.5M as of Dec 31, 2025.
- 6,629 unique patient prescriptions for Attruby written by 1,632 prescribers as of Dec 31, 2025, reflecting rapid adoption.
- New TTR amyloid depleter antibody program to explore ATTR-CM disease reversal; clinic expected between 2027-2028.
- FDA recommends NDA for BBP-418 (LGMD2I/R9) toward full approval after positive FORTIFY interim; submission planned H1 2026.
- Encumeret NDA for ADH1 planned H1 2026; Phase 3 RECLAIM-HP in chronic hypoparathyroidism to start summer 2026.

## SEC filing metadata
- accession: 0001140361-26-000971
- form_type: 8-K
- ticker: BBIO
- cik: 0001743881
- company_name: BridgeBio Pharma, Inc.
- filed_at: 2026-01-12T23:59:59+00:00
- event_type: other_material
- sentiment: positive
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 2.02, 7.01, 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1743881/000114036126000971/0001140361-26-000971-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1743881/000114036126000971/ef20062706_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001140361-26-000971
- JSON: https://secwatch.observer/filing/0001140361-26-000971.json
- Plain text: https://secwatch.observer/filing/0001140361-26-000971.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.